Acasti Pharma, Inc. (ACST) - NASDAQ
  • Tue, Jul. 12, 6:36 AM
    • Acasti Pharma (ACST) Q1 results: Revenues: $0; R&D Expense: $2.4M (+20.0%); Operating Loss: ($2.3M) (-21.1%); Net Loss: ($3.2M); Loss Per Share: ($0.29); Quick Assets: $9.6M.
    • No guidance given.
    | Tue, Jul. 12, 6:36 AM
  • Mon, Jul. 11, 5:48 PM
    | Mon, Jul. 11, 5:48 PM
  • Thu, May 26, 8:23 AM
    • Acasti Pharma (ACST) FQ4 results: Revenues: $21K (-88.2%); R&D Expense: $1.8M (-21.7%); Net Loss: ($1.9M) (+17.4%); Loss Per Share: ($0.18) (+14.3%).
    • FY2016 results: Revenues: $38K (-86.0%); R&D Expense: $7.4M (-16.9%); Net Loss: ($6.3M) (-270.6%); Loss Per Share: ($0.59) (-268.8%); Quick Assets: $12.5M.
    • No guidance given.
    | Thu, May 26, 8:23 AM
  • Wed, May 25, 5:09 PM
    • Acasti Pharma (NASDAQ:ACST): FQ4 EPS of -$0.18
    • Revenue of $21K (-88.2% Y/Y).
    • Press Release
    | Wed, May 25, 5:09 PM
  • Thu, May 12, 9:15 AM
    • Acasti Pharma (NASDAQ:ACST) appoints Jan D'Alvise as President & CEO effective June 1. Previously, she was President and Chairman of Pediatric Bioscience. Before that, she was CEO of Gish Biomedical.
    | Thu, May 12, 9:15 AM
  • Wed, Jan. 13, 7:14 AM
    • Acasti Pharma (ACST) Q3 results: Revenues: $0; R&D Expense: $1.4M (-17.6%); Adjusted EBITDA: ($2M) (+4.8%); Net Loss: ($2.2M) (-173.3%); Quick Assets: $14.1M.
    • No guidance given.
    | Wed, Jan. 13, 7:14 AM
  • Tue, Jan. 12, 5:17 PM
    • Acasti Pharma (NASDAQ:ACST): Q3 Net loss of $2.19M
    | Tue, Jan. 12, 5:17 PM
  • Dec. 16, 2015, 12:45 PM
    | Dec. 16, 2015, 12:45 PM
  • Dec. 16, 2015, 9:29 AM
    • Thinly traded nano cap Acasti Pharma (NASDAQ:ACST) is up 28% premarket on light volume in response to its announcement that the FDA has clarified the development pathway for CaPre, a highly concentrated omega-3 phospholipid derived from krill oil that is being investigated for the potential treatment of certain cardiometabolic disorders.
    • The company believes it will be able to pursue regulatory clearance using the streamlined 505(b)(2) pathway which allows some of the supporting data to be derived from studies performed by others.
    • Acasti will submit an amendment to its IND application that will clear the way for a bioavailability bridging study that will compare CaPre to another FDA-approved omega-3 prescription drug with the aim of establishing a scientific bridge between the two. This will determine the feasibility of a 505(b)(2) pathway while optimizing the design of a Phase 3 trial.
    | Dec. 16, 2015, 9:29 AM
  • Oct. 15, 2015, 8:55 AM
    • Acasti Pharma (ACST) FQ2 results: Revenues: $7M (-6.7%); COGS: $2.3M (-48.9%); R&D Expense: $1.1M (-38.9%); SG&A: $1M (-41.2%); Operating Loss: ($2.2M) (+37.1%); Net Loss: ($1.2M) (+67.6%); Loss Per Share: ($0.01) (+66.7%); Quick Assets: $15.8M (-14.1%).
    • No guidance given.
    | Oct. 15, 2015, 8:55 AM
  • Oct. 14, 2015, 5:15 PM
    • Acasti Pharma (NASDAQ:ACST): Q2 Net loss of $1.24M
    | Oct. 14, 2015, 5:15 PM
  • Jul. 14, 2015, 7:15 AM
    • Acasti Pharma (ACST +9.1%) FQ1 results: Revenues: $5K (-91.1%); R&D Expense: $1.3M (+8.3%); Adjusted EBITDA Loss: ($1.9M) (-11.8%); Net Loss: ($1M) (-171.4%); Quick Assets: $17.2M.
    • No guidance given.
    | Jul. 14, 2015, 7:15 AM
  • Jul. 13, 2015, 5:17 PM
    • Acasti Pharma (NASDAQ:ACST): FQ1 Net loss of $0.97M vs. profit of $1.36M in Q114
    | Jul. 13, 2015, 5:17 PM | 1 Comment
  • May 28, 2015, 8:23 AM
    • Acasti Pharma (ACST -2.9%) FQ4 results: Revenues: $178K (-11.4%); R&D Expense: $1.8M (+157.1%); Adjusted EBITDA Loss: ($2.3M) (-130.0%); Net Loss: ($2.3M) (+11.5%); Loss Per Share: ($0.02) (unch).
    • FY2015 results: Revenues: $271K (-45.9%); R&D Expense: $6.5M (+51.2%); Adjusted EBITDA Loss: ($8.5M) (-51.8%); Net Loss: ($1.7M) (+85.3%); Loss Per Share: ($0.02) (+85.7%).
    • No guidance given.
    | May 28, 2015, 8:23 AM
  • May 27, 2015, 5:50 PM
    • Acasti Pharma (NASDAQ:ACST): FQ4 EPS of -$0.02
    • Revenue of $0.18M (-10.0% Y/Y)
    | May 27, 2015, 5:50 PM
  • Apr. 30, 2015, 3:59 PM
    • Acasti Pharma (ACST -3.3%) CFO Andre Godin ends his tenure effective immediately. The reasons for his departure are not disclosed.
    | Apr. 30, 2015, 3:59 PM
Company Description
Acasti Pharma, Inc. is a biopharmaceutical company, which engages in the research, development and commercialization of proprietary active pharmaceutical ingredients for the management of cardio metabolic disorders, from prevention to treatment and through a novel superior approach to lipid... More
Sector: Healthcare
Country: Canada